Cover image for Vol. 119 Issue 14

15 July 2013

Volume 119, Issue 14

Pages 2515–2663

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
    2. You have free access to this content
    3. You have free access to this content
  2. Original Articles

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Correspondence
    1. Disease Site

      Breast Disease
      Trends in mammography screening rates after publication of the 2009 US Preventive Services Task Force recommendations (pages 2518–2523)

      Lydia E. Pace, Yulei He and Nancy L. Keating

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28105

      Mammography rates in the United States did not decrease among women aged >40 years after publication of the US Preventive Services Task Force recommendations in 2009. It appears likely that the vigorous policy debates and coverage in the media and medical literature impacted the adoption of these recommendations by patients, providers, or both.

    2. The effect of nurse navigation on timeliness of breast cancer care at an academic comprehensive cancer center (pages 2524–2531)

      Mohua Basu, Jared Linebarger, Sheryl G. A. Gabram, Sharla Gayle Patterson, Miral Amin and Kevin C. Ward

      Article first published online: 12 APR 2013 | DOI: 10.1002/cncr.28024

      Nurse navigation was found to significantly shorten time to consultation for breast cancer patients older than 60 years. Further studies are indicated to assess the long-term effects and durability of this quality improvement initiative.

    3. Expression of androgen receptor and its phosphorylated forms in breast cancer progression (pages 2532–2540)

      Qinghu Ren, Liying Zhang, Rachel Ruoff, Susan Ha, Jinhua Wang, Shilpa Jain, Victor Reuter, William Gerald, Dilip D. Giri, Jonathan Melamed, Michael J. Garabedian, Peng Lee and Susan K. Logan

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28092

      AR and its phosphorylation at serines 213 and 650 are differentially expressed in breast cancer tumorigenesis and progression. Phosphorylation of AR at serines 213 and 650 is increased in ER-negative breast cancers, ductal carcinomas, and metastases and may have predictive value in breast cancer prognosis.

    4. You have full text access to this OnlineOpen article
      Which strategies reduce breast cancer mortality most?: Collaborative modeling of optimal screening, treatment, and obesity prevention (pages 2541–2548)

      Jeanne Mandelblatt, Nicolien van Ravesteyn, Clyde Schechter, Yaojen Chang, An-Tsun Huang, Aimee M. Near, Harry de Koning and Ahmedin Jemal

      Article first published online: 26 APR 2013 | DOI: 10.1002/cncr.28087

      Two simulation models examine 6 strategies: combinations of increased screening and/or receipt of indicated treatment or elimination of obesity are compared to continuation of current patterns. Maximal reductions in breast cancer deaths could be achieved by 2025 through optimizing treatment use, followed by increasing screening use and then obesity prevention.

    5. Gastrointestinal Disease
      Computed tomographic colonography for colorectal cancer screening: Risk factors for the detection of advanced neoplasia (pages 2549–2554)

      Cesare Hassan, B. Dustin Pooler, David H. Kim, Antonio Rinaldi, Alessandro Repici and Perry J. Pickhardt

      Article first published online: 10 JUN 2013 | DOI: 10.1002/cncr.28007

      When stratifying a large computed tomographic colonography (CTC) screening cohort according to age and sex, the number of individuals who would have to undergo CTC screening to detect 1 advanced neoplasm ranges from 51 among women aged <55 years to 10 among men aged >65 years. The possibility of stratifying the population undergoing CTC screening according to the risk of advanced neoplasia may prompt the development of more efficient risk-reduction strategies.

    6. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study (pages 2555–2563)

      Jeffrey R. Infante, Tony R. Reid, Allen L. Cohn, William J. Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald A. Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim and Thomas H. Cartwright

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28112

      This randomized, phase 2 trial shows that objective response rates and progression-free and overall survival are numerically inferior in patients who receive axitinib plus combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6) versus bevacizumab plus FOLFOX-6. Shorter treatment duration and more discontinuations because of adverse events observed in the axitinib arm suggest that vascular endothelial growth factor receptor tyrosine kinase inhibitors plus chemotherapy may be somewhat less well tolerated than bevacizumab plus chemotherapy.

    7. Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer (pages 2564–2573)

      Pasquale F. Innominato, Sylvie Giacchetti, Thierry Moreau, Georg A. Bjarnason, Rune Smaaland, Christian Focan, Carlo Garufi, Stefano Iacobelli, Marco Tampellini, Salvatore Tumolo, Carlos Carvalho, Abdoulaye Karaboué, Antoine Poncet, David Spiegel, Francis Lévi and for the International Association for Research on Time in Biology and Chronotherapy (ARTBC) Chronotherapy Group

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28072

      Circadian-based chemotherapy, which accounts for physiologic oscillations in biologic functions over 24 hours, achieves the best efficacy when good tolerance occurs. The main clinical implication of the current study is that optimization of circadian-based delivery should allow concomitant improvements in the safety and efficacy of chemotherapy with increased benefit for the individual patient.

    8. Genitourinary Disease
      Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older (pages 2574–2581)

      Darren R. Feldman, Martin H. Voss, Erin P. Jacobsen, Xiaoyu Jia, J. Andres Suarez, Stefan Turkula, Joel Sheinfeld, George J. Bosl, Robert J. Motzer and Sujata Patil

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28025

      Because germ cell tumors are rare in men aged ≥ 50 years, there is limited knowledge regarding the clinical characteristics and outcomes, including treatment tolerability in this population. This retrospective study provides important data on differences in histology and primary tumor site distribution for older versus younger men and details the increased rate of complications that occur in older men with germ cell tumors who are treated with chemotherapy.

    9. Gynecologic Oncology
      Tubulin-β-III overexpression by uterine serous carcinomas is a marker for poor overall survival after platinum/taxane chemotherapy and sensitivity to epothilones (pages 2582–2592)

      Dana M. Roque, Stefania Bellone, Diana P. English, Natalia Buza, Emiliano Cocco, Sara Gasparrini, Ileana Bortolomai, Elena Ratner, Dan-Arin Silasi, Masoud Azodi, Thomas J. Rutherford, Peter E. Schwartz and Alessandro D. Santin

      Article first published online: 12 APR 2013 | DOI: 10.1002/cncr.28017

      Uterine serous carcinomas represent an aggressive variant of endometrial cancer that overexpress tubulin-β-III relative to ovarian serous carcinomas. Among patients with advanced-stage disease, tubulin-β-III overexpression by quantitative real-time polymerase chain reaction or immunohistochemistry stratifies patients who are simultaneously at risk of reduced overall survival after platinum/taxane combination chemotherapy and likely to respond to epothilones.

    10. Head and Neck Disease
      Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers (pages 2593–2601)

      Samuel J. Gan, Kristina R. Dahlstrom, Brandon W. Peck, Wes Caywood, Guojun Li, Qingyi Wei, Mark E. Zafereo and Erich M. Sturgis

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28107

      The 3-year and 5-year rates of second primary malignancy are lower for patients with index squamous cell carcinoma of the oropharynx than for patients with index nonoropharyngeal cancer. In patients with squamous cell carcinoma of the head and neck, index cancer site and smoking status affect the risk and distribution of second primary malignancies.

    11. Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009 (pages 2602–2610)

      Benjamin Ansa, Michael Goodman, Kevin Ward, Scott A. Kono, Taofeek K. Owonikoko, Kristin Higgins, Jonathan J. Beitler, William Grist, Trad Wadsworth, Mark El-Deiry, Amy Y. Chen, Fadlo Raja Khuri, Dong M. Shin and Nabil F. Saba

      Article first published online: 14 MAY 2013 | DOI: 10.1002/cncr.28108

      Although there has been a decline in the proportion of patients presenting with advanced paranasal sinus squamous cell carcinoma, overall survival has remained stable over time. There appears to be evidence of racial disparity in the incidence and (to a lesser extent) the outcome of paranasal sinus squamous cell carcinoma.

    12. Hematologic Malignancies
      Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia (pages 2611–2619)

      Hagop M. Kantarjian, Giovanni Martinelli, Elias J. Jabbour, Alfonso Quintás-Cardama, Kiyoshi Ando, Jacques-Olivier Bay, Andrew Wei, Stefanie Gröpper, Cristina Papayannidis, Kate Owen, Laura Pike, Nicola Schmitt, Paul K. Stockman, Aristoteles Giagounidis and on behalf of the SPARK-AML1 Investigators

      Article first published online: 19 APR 2013 | DOI: 10.1002/cncr.28113

      A significant improvement in the objective complete response rate is observed with 1200 mg barasertib versus 400 mg low-dose cytosine arabinoside in older patients with acute myeloid leukemia. The safety profile of barasertib, although more toxic than that of low-dose cytosine arabinoside, is manageable and consistent with previous studies.

    13. Trends in all-cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology, and End Results database analysis (pages 2620–2629)

      Andrew M. Brunner, Federico Campigotto, Hossein Sadrzadeh, Benjamin J. Drapkin, Yi-Bin Chen, Donna S. Neuberg and Amir T. Fathi

      Article first published online: 26 APR 2013 | DOI: 10.1002/cncr.28106

      Patients with chronic myeloid leukemia have experienced improvements in overall survival among all age groups. Nonetheless, elderly patients continue to have worse outcomes when examined at the population level.

    14. Neuro-Oncology
      Long-term outcome of centrally located low-grade glioma in children (pages 2630–2638)

      Keita Terashima, Kevin Chow, Jeremy Jones, Charlotte Ahern, Eunji Jo, Benjamin Ellezam, Arnold C. Paulino, M. Fatih Okcu, Jack Su, Adekunle Adesina, Anita Mahajan, Robert Dauser, William Whitehead, Ching Lau and Murali Chintagumpala

      Article first published online: 26 APR 2013 | DOI: 10.1002/cncr.28110

      Although effective and durable tumor control is attainable with radiation therapy in older patients, frequent progression and long-term morbidity is common in young patients who undergo chemotherapy to delay the use of radiation therapy.

    15. Discipline

      Medical Oncology
      Sorafenib in patients with progressive epithelioid hemangioendothelioma: A phase 2 study by the French Sarcoma Group (GSF/GETO) (pages 2639–2644)

      Christine Chevreau, Axel Le Cesne, Isabelle Ray-Coquard, Antoine Italiano, Angela Cioffi, Nicolas Isambert, Yves Marie Robin, Charles Fournier, Stéphanie Clisant, Loic Chaigneau, Jacques-Olivier Bay, Emmanuelle Bompas, Eric Gauthier, Jean Y. Blay and Nicolas Penel

      Article first published online: 15 APR 2013 | DOI: 10.1002/cncr.28109

      The authors report on a phase 2 trial investigating sorafenib as treatment for progressive epithelioid hemangioendothelioma. Two partial responses (in 2 of 15 patients) are observed, and the 9-month progression-free rate is 38.4% (4 of 13 patients).

    16. Pediatric Oncology
      Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience (pages 2645–2653)

      Sarah E. S. Leary, Amy W. Wozniak, Catherine A. Billups, Jianrong Wu, Valerie McPherson, Michael D. Neel, Bhaskar N. Rao and Najat C. Daw

      Article first published online: 26 APR 2013 | DOI: 10.1002/cncr.28111

      Patients with relapsed osteosarcoma have a poor prognosis. Whereas surgery is essential for survival, chemotherapy may slow disease progression in patients without remission. This study provides data on prognostic factors and event-free survival after relapse that are needed for the design of phase 2 trials of novel agents.

    17. Intensity-modulated radiotherapy (IMRT) in pediatric low-grade glioma (pages 2654–2659)

      Arnold C. Paulino, Ali Mazloom, Keita Terashima, Jack Su, Adekunle M. Adesina, M. Faith Okcu, Bin S. Teh and Murali Chintagumpala

      Article first published online: 30 APR 2013 | DOI: 10.1002/cncr.28118

      Intensity-modulated radiation therapy provides local control rates comparable to those achieved with 2-dimensional and 3-dimensional radiotherapy in pediatric patients with low-grade glioma. Margins ≥1 cm added to the gross tumor volume to create the clinical target volume may not be necessary, because excellent local control is achieved by adding a 0.5-cm margin to the clinical target volume and by dose painting.

  3. Correspondence

    1. Top of page
    2. CancerScope
    3. Original Articles
    4. Correspondence